Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yvette Meissner

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Journal of Pharmaceutical Sciences|October 24, 2007
Alternative drug delivery approaches for the therapy of inflammatory bowel diseaseYvette Meissner, Alf Lamprecht
International Journal of Pharmaceutics|May 6, 2006
Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive deliveryYvette Meissner, Yann Pellequer, Alf Lamprecht
The Journal of Pharmacology and Experimental Therapeutics|February 27, 2007
Epithelial heparin delivery via microspheres mitigates experimental colitis in miceYann Pellequer, Yvette Meissner, Nathalie Ubrich, et al.
Seminars in Arthritis and Rheumatism|April 22, 2021
Pregnancy in women with psoriatic arthritis: A systematic literature review of disease activity and adverse pregnancy outcomesYvette Meissner, Tatjana Rudi, Rebecca Fischer-Betz, et al.
Best Practice & Research. Clinical Rheumatology|October 15, 2024
Role of rheumatoid arthritis registries worldwide: What have they taught us?Paul Studenic, Yvette Meissner, Lianne Kearsley-Fleet, et al.
International Journal of Pharmaceutics|December 8, 2006
Low molecular weight heparin loaded pH-sensitive microparticlesYvette Meissner, Nathalie Ubrich, Fatima El Ghazouani, et al.
RMD Open|October 25, 2023
Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT registerYvette Meissner, Martin Schäfer, Katinka Albrecht, et al.
Clinical Rheumatology|April 8, 2026
Sex-specific traditional and disease-related risk factors for incident heart failure in patients with rheumatoid arthritis: a registry-based cohort studyVera Zietemann, Tatjana Rudi, Daniel Bestler, et al.
Arthritis Research & Therapy|December 5, 2024
Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBITRonja Ramien, Tatjana Rudi, Rieke Alten, et al.
RMD Open|April 5, 2024
Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT registerTatjana Rudi, Vera Zietemann, Yvette Meissner, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Journal of Pharmaceutical Sciences|October 24, 2007
Alternative drug delivery approaches for the therapy of inflammatory bowel diseaseYvette Meissner, Alf Lamprecht
International Journal of Pharmaceutics|May 6, 2006
Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive deliveryYvette Meissner, Yann Pellequer, Alf Lamprecht
The Journal of Pharmacology and Experimental Therapeutics|February 27, 2007
Epithelial heparin delivery via microspheres mitigates experimental colitis in miceYann Pellequer, Yvette Meissner, Nathalie Ubrich, et al.
Seminars in Arthritis and Rheumatism|April 22, 2021
Pregnancy in women with psoriatic arthritis: A systematic literature review of disease activity and adverse pregnancy outcomesYvette Meissner, Tatjana Rudi, Rebecca Fischer-Betz, et al.
Best Practice & Research. Clinical Rheumatology|October 15, 2024
Role of rheumatoid arthritis registries worldwide: What have they taught us?Paul Studenic, Yvette Meissner, Lianne Kearsley-Fleet, et al.
International Journal of Pharmaceutics|December 8, 2006
Low molecular weight heparin loaded pH-sensitive microparticlesYvette Meissner, Nathalie Ubrich, Fatima El Ghazouani, et al.
RMD Open|October 25, 2023
Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT registerYvette Meissner, Martin Schäfer, Katinka Albrecht, et al.
Clinical Rheumatology|April 8, 2026
Sex-specific traditional and disease-related risk factors for incident heart failure in patients with rheumatoid arthritis: a registry-based cohort studyVera Zietemann, Tatjana Rudi, Daniel Bestler, et al.
Arthritis Research & Therapy|December 5, 2024
Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBITRonja Ramien, Tatjana Rudi, Rieke Alten, et al.
RMD Open|April 5, 2024
Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT registerTatjana Rudi, Vera Zietemann, Yvette Meissner, et al.
Pageof 3